WINNERSH, UNITED KINGDOM--(Marketwired - Aug 20, 2015) - Vernalis plc today announces the results from a Phase II proof-of-concept (POC) study of V158866, its fatty acid amide hydrolase (FAAH) inhibitor, which is being investigated as a treatment for neuropathic pain as a result of spinal cord injury.